Navigation Links
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Date:9/5/2007

cations, warnings and precautions, see the Instructions for Use available at http://www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.


'/>"/>
SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... with certain of its shareholders, has closed the transaction ... ("Medna").  Medna has acquired (the "Escrow Transfer") a total ...
(Date:4/24/2015)... -- Elekta has CE marked the latest version (v5.10) of ... European clinics to deliver a sophisticated radiation therapy planning ... planning, IMRT, VMAT and stereotactic planning – all in ... ® v5.10 provides significant planning and ... 3D planning as well as the addition of MRI ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Elekta CE marks for Monaco v5.10 treatment planning system 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... Knopp Neurosciences Inc. ("Knopp"),announced that the U.S. ... Development has granted orphan drug designation to ... (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... studies to evaluate the safety,tolerability and pharmacokinetics ...
... on stringent endpoint of clinical ... PHILADELPHIA, Oct. 15 An analysis of data to,be ... Scientific Meeting found that Asacol, dosed at 2.4 g/day, ... active,ulcerative colitis (UC). The analysis was based on data ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 3New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 4
(Date:4/25/2015)... In the United States alone, an ... treatment for an illicit drug or alcohol ... Mental Health Services Administration’s Survey on Drug Use and ... are harrowing stories of men and women whose lives ... David H. Kerr , founder and retired president of ...
(Date:4/25/2015)... New York, NY (PRWEB) April 25, 2015 ... systems, technology and data for the enterprise relying on their ... and running smoothly. But according to an article ... CIOs can many times actually be doing a disservice to ... the i’s are dotted and t’s are crossed when it ...
(Date:4/25/2015)... Gardant Management Solutions will lead ... operations, and sales and marketing at the LeadingAge ... be held from April 29 through May 1 ... largest eldercare association in Illinois. The statewide association ... adults, including senior housing, assisted living and supportive ...
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse and violence. ... the Miami Dolphins and Richie Incognito, or off the field and ... abuse case. In a recent episode of SCI TV , ... locker room culture on teams. He examines what worked for the ... improve the locker room as a work place. , Steele ...
(Date:4/24/2015)... 24, 2015 Bird B Gone, the leader ... now offers a complete line of bird control solutions to ... , New Flu Strains Threaten Pacific, Central and Mississippi Farms ... , a number of highly pathogenic avian flus in ... is often spread when wild birds enter poultry farms. The ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4
... back, the 2008 Compensation Data results show benefits have seen little change ... ... October 29, 2008 -- General Motors has made headlines with plans to ... Retirees are also slated to loose health insurance coverage when they reach ...
... commercial with Jenny,Craig celebrity client, Valerie Bertinelli, ... pleased to,announce the three grand finalists of their ... Elaina Faustino and,Sara Hennessy are the three women ... TV commercial with Jenny Craig star client, Valerie ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (WorldHeart or ... filing of articles of amendment with Industry,Canada under the ... Capital Market on a post-consolidation basis on October 28,2008. ... split at a Special Meeting of Shareholders held on ...
... Quarter Net Sales of $3.9 Million; 29% Increase ... - Second Fiscal Quarter U.S. Sales of $2.2 Million; 83% Increase ... Year-Over-Year -, - Multicenter Clinical Study Launched to Expand Reimbursement, Support ... Marketing - - Conference Call to be Held ...
... Oct. 29 Heralding the newest innovation,in home skin ... of light therapy, has announced the retail launch of ... Quasars are widely,acclaimed as the first professional devices made ... the Baby Quasar delivers exceptional,skin care results and can ...
... cloud symptoms, study says , , WEDNESDAY, Oct. 29 (HealthDay News) ... in people if they have other medical conditions, a new ... high cholesterol appeared to mask early MS symptoms and lead ... in the Oct. 29 online issue of Neurology . ...
Cached Medicine News:Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 2Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 3Health News:Jenny Craig Announces Finalists for the 2008 Ideal Size Contest 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 2Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 4Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 5Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 6Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 7Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 8Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 9Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 10Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 11Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 12Health News:Baby Quasar Lights Up Dillard's for the Retail Holiday Season 2Health News:Other Health Problems Can Delay MS Diagnosis 2
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
... Ankle/Brachial Index (ABI) testing, Nicolet Vascular has ... It includes a 10-minute compact disk ABI ... any computer with a CD drive. It ... ABI test, provides information on the materials ...
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
Medicine Products: